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Abstract: Olfactory involvement is well recognized in patients with Parkinson’s disease (PD). 
The purpose of this study was to examine smell function quantitatively, using different types 
and concentrations of odorants in PD patients. We aimed to elucidate whether a specific odor 
can affect the severity and duration of PD patients. A total of 89 nondemented PD patients and 
20 age-matched controls participated in the study. Quantitative evaluation of smell function 
was performed using the T and T olfactometer test. This test contains five kinds of odorants at 
different concentrations. Recognition threshold (RT) scores for all five odorants and for each 
individual odorant were measured in five groups of PD patients with Hoehn and Yale (HY) 
stages I (n = 12), II (n = 24), III (n = 43), and IV (n = 10), as well as in control subjects (n = 20). 
One-way analysis of variance and Ryan’s method were used for statistical comparison between 
the five groups. Compared with controls and HY I patients, total RT scores were significantly 
higher in HY II, III, and IV patients. There were no statistically significant differences in RT 
scores between HY I patients and controls. However, total RT scores for three HY I patients 
(25%) were higher than the mean + two standard deviations of controls. On single odorant 
testing, significant higher RT scores for methylcyclopentenolone and skatol were found in HY 
II, III, and IV patients, in comparison with controls and HY I patients. The remaining three 
odorants did not differ statistically between PD patients and control subjects. The present study 
indicated that hyposmia in PD patients increased from HY II onwards. A single odorant of 
methyl cyclopentenolone or skatol had benefits for olfactory evaluation in PD patients. Our data 
also clarified that olfactory deficits occurred in a subset of HY I patients. Further prospective 
study is needed to elucidate whether a distinct profile of PD exists between HY I patients with 
and without hyposmia.
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Introduction
Olfactory impairment in Parkinson’s disease (PD) was first described by Ansari and 
Johnson.1 The frequency of olfactory dysfunction is 70%–90% in PD patients,2 and 
rates of hyposmia correspond to presence of tremor.3 Neuropathologic research in PD 
patients suggests neuronal damage in the olfactory system, including the olfactory bulb 
and the anterior olfactory nucleus.4 There have been many studies of the relationship 
between olfactory deficits and PD progression.5–8 Several studies showed that PD 
  progression was correlated with olfactory dysfunction.6–8 Tissingh et al7 pointed out that 
odor discrimination was negatively associated with the Unified Parkinson’s Disease 
Rating Scale (UPDRS) and Hoehn and Yale (HY) stage. This suggests that olfactory 
tests may have benefits for early diagnosis of PD. Previous olfactory tests used single or International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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several kinds of odorants.5–8 The T and T olfactometer (TTO) 
test is a quantitative smell test that contains five odorants and 
different concentrations of each odorant. The present study 
was designed to evaluate how useful TTO is as a tool for 
detection of hyposmia in PD patients and the relationship 
between hyposmia and disease progression.
Methods
PD patients and control subjects
PD was diagnosed according to the UK Parkinson’s Disease 
Society Brain Bank criteria. A total of 89 patients with PD and 
20 age-matched healthy controls participated in the study (see 
Table 1). Mean age (± standard deviation, SD) was 69.1 (7.1) 
years in PD patients and 68.3 (8.2) years in controls. Mean 
disease duration was 5.6 (4.6) years. PD severity was classi-
fied by HY criteria, and mean HY stage was 2.5 (0.9). Patients 
were categorized as HY I (n = 12), II (n = 24), III (n = 43) 
and IV (n = 10). PD patients with dementia, defined accord-
ing to Mini Mental State   Examination scores lower than 22 
points, were excluded. Before the smell examination, all PD 
patients had had an otorhinolaryngology consultation, and 
those with suspected rhinologic disorders underwent further 
examination, including nasal endoscopy. PD patients and 
control subjects who had severe rhinologic disease causing 
respiratory hyposmia, such as chronic or acute sinusitis, 
allergic rhinitis, nasal polyps, tumors, or severe septal devia-
tion were excluded. PD patients with olfactory hallucinations 
on rhinologic examination were also excluded. The present 
study was performed and approved according to the clini-
cal guidelines of Sagamihara National Hospital. Informed 
consent was obtained from all study participants.
Quantitative olfactory test
Olfactory function was evaluated using the TTO test 
(Takasago Co., Tokyo). Olfactory examination was 
  undertaken in a special odorless room. The temperature of 
the room was adjusted to 23°C. Adequate air   ventilation 
was maintained. Previous data show that the results of this 
test have a good correlation with the University of Penn-
sylvania Smell Identification Test (UPSIT).9 The TTO test 
used five kinds of odorants, comprising A (β-phenyl ethyl 
  alcohol), B   (methyl cyclopentenolone), C (isovaleric acid), 
D (γ-undecalactone), and E (skatol). The A odor was rose-
scented (“rose”), B charred (“caramel”), C rancid (“putre-
faction”), D peach-like (“peach”), and E halitosis-like 
(“feces”). Seven or eight sequential dilutions of each odor-
ant were prepared. Each odorant was judged by a numeric 
score of -2–5 according to its concentration. Each odor test 
was performed gradually from the lowest concentration (-2) 
to higher concentrations. The subject was asked to sniff a 
paper edge soaked in an odorant and to describe the nature 
of the odor. Recognition threshold (RT) was defined as 
the lowest concentration at which a subject described the 
type of odor correctly. A patient could answer “rose” or 
“sweet-scented flower” for the odorant A test. Similarly, 
the correct response to odorant B was “caramel” or “burnt 
sugar”. Odorant C could be answered as “rancid”, “rotten 
food” or “sweaty clothes”. Odorant D could be answered as 
“peach-like” or “sweet fruit”. Odorant E could be answered 
as “halitosis-like”, “feces” or “kitchen”. The test was 
repeated from odorant A to E in sequence. When a patient 
failed to identify the odor at the highest possible concentra-
tion of odors A to E accurately, the score was determined 
as six points. Total RT was calculated as the average of five 
odorant scores ([A + B + C + D + E]/5). A larger RT value 
indicated more severe olfactory dysfunction. The detection 
threshold (DT) of the TTO test was assessed only by the 
presence or absence of smell. Therefore, DT did not can-
vas the correct type or character of each odorant. DT was 
therefore not used for quantitative evaluation of olfactory 
function in this study.
statistical analysis
All data were shown as mean (SD). One-way analysis 
of   variance (ANOVA) and Ryan’s method were used to 
  compare RT scores for the four PD groups of HY I–IV 
patients and the control group. After one-way ANOVA, 
Ryan’s method was performed for multiple comparisons. 
The level of significance was set at P , 0.05 for both 
tests.
Table 1 Clinical profile of Parkinson’s disease patients and control subjects
Control (n = 20) Total HY I (n = 12) HY II (n = 24) HY III (n = 43) HY IV (n = 10)
Male/female 5/15 35/54 5/7 11/13 16/27 3/7
Mean age (sD) years 68.3 (8.2) 69.1 (7.1) 68.2 (6.8) 67.0 (7.8) 70.5 (7.9) 69.5 (9.5)
Mean duration of PD (sD) years 5.6 (4.6) 1.9 (1.6) 4.8 (3.6) 5.8 (4.4) 11.0 (5.6)
Mean MMse score (sD) 27.6 (2.2) 25.8 (2.8) 26.8 (2.9) 26.0 (3.1) 25.1 (2.3) 25.8 (2.9)
Abbreviations: hY, hoehn and Yale; MMse, mini-mental state examination; PD, Parkinson’s disease; sD, standard deviation.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Results
The mean value (SD) of total RT scores were 2.6 (0.6) 
in control subjects, 2.1 (1.5) in HY I, 3.8 (1.2) in HY 
II, 3.9 (1.4) in HY III, and 3.9 (1.6) in HY IV patients 
(Figure 1). Total RT scores were significantly higher in 
the HY II, HY III, and HY IV groups compared with the 
control group and the HY I group (F = 8.154, P , 0.001 
by one-way ANOVA, P , 0.01 by Ryan’s method). These 
results suggest that olfactory dysfunction occurred in PD 
patients with HY II disease onwards. Three HY I patients 
(25%) had higher than the mean + 2 SD total RT scores 
for controls. Mean RT scores of odorant A were 3.4 (1.4) 
in controls, 3.3 (2.7) in HY I, 4.8 (1.8) in HY II, 4.8 (1.8) 
in HY III, and 4.0 (2.3) in HY IV patients. These scores 
did not differ between the four groups of HY I–IV patients 
and controls (Figure 2A). Mean RT scores of odorant B 
were 2.2 (1.3) in controls, 1.8 (1.8) in HY I, 3.9 (1.7) in 
HY II, 3.9 (1.6) in HY III, and 4.6 (1.5) in HY IV patients 
Total RT score
6
4
2
0
Controls HY I HY II HY III HY IV
*† *† *†
Figure 1 Total RT scores of five odorants in PD patients and control subjects. 
compared with controls or hY I patients, total rT scores were higher in hY II, III, 
and IV patients (F = 8.154 and P , 0.001 by one-way AnOVA).
Notes: *P , 0.01 by ryan’s method among the PD subgroups of hY II, III, and IV, and 
the control group; †P , 0.01 by ryan’s method between the hY I group and other hY 
groups.
Abbreviations:  AnOVA,  one-way  analysis  of  variance;  hY,  hoehn  and  Yale;   
PD, Parkinson’s disease; rT, recognition threshold.
Odor A: β-phenyl ethyl alcohol
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Figure 2A RT score of odorant A. There were no significant differences of odorant 
A scores between the five groups.
Odor B: methyl cyclopentenolone
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*† *†
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Figure 2B  rT score of odorant B. compared with controls and hY I patients, rT 
scores for odorant B were significantly higher in HY II, III, and IV patients. (F = 8.848, 
P , 0.001 by one-way AnOVA). 
Notes: *P , 0.01 by ryan’s method between the PD hY II, III, and IV subgroups 
and controls; †P , 0.01 by ryan’s method between the hY I group and other hY 
groups.
(Figure 2B). RT scores of HY II, III, and IV patients were 
significantly higher than those of controls and HY I patients 
(F = 8.848, P , 0.001 by one-way ANOVA, P , 0.01 by Ryan’s 
method). Mean RT scores of odorant C were 2.0 (1.2) in controls, 
1.0 (1.6) in HY I, 3.3 (1.8) in HY II, 3.2 (1.7) in HY III, and 
3.0 (1.9) in HY IV patients (Figure 2C). Compared with HY I 
patients, RT scores of odorant C were increased significantly in 
HY II, III, and IV patients (F = 16.294, P , 0.001 by one-way 
ANOVA, P , 0.01 by Ryan’s method). These scores did not 
differ statistically between any of the four PD subgroups and 
controls. Mean scores of odorant D were 3.0 (1.3) in controls, 
2.6 (2.1) in HY I, 3.0 (1.7) in HY II, 3.7 (1.9) in HY III, and 
3.8 (2.2) in HY IV patients (Figure 2D). RT scores of odorant 
D did not differ significantly between the HY I, II, III, and IV 
patients and controls. Mean scores of odorant E were 1.8 (1.0) 
in controls, 2.1 (2.0) in HY I, 4.1 (2.1) in HY II, 4.0 (2.1) in HY 
III, and 4.3 (2.0) in HY IV patients (Figure 2E). Those scores 
were significantly higher in HY II, III, and IV patients than in 
controls or HY I patients (F = 27.876, P , 0.001 by one-way 
ANOVA, P , 0.01 by Ryan’s method).
Odor C: isovaleric acid
6
4
2
0
Controls HY I HY II HY III HY IV
* * *
Figure 2C rT score of odorant c. compared with hY I patients, rT scores of 
odorant C were increased significantly in HY II, III, and IV patients (F = 16.294 and 
P , 0.001 by one-way AnOVA). 
Note: *P , 0.01 by ryan’s method.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Discussion
The present study showed that olfactory function in PD 
patients declined in a statistically significant manner from HY 
II onwards. There were no statistically significant differences 
between HY I patients and controls, although three of 12 
patients with HY I had hyposmia in comparison with controls. 
Comparative analyses of five odorants revealed that odorant 
B (methyl cyclopentenolone) and E (skatol) were involved in 
PD patients with HY II–IV . RT scores of odorant C (isovaleric 
acid) were significantly lower in HY I than in HY II, III, and IV 
patients, whereas no statistically significant differences existed 
between the HY stage PD subgroups and controls.
The association between olfactory deficits and PD 
progression has been controversial in previous reports. On 
UPSIT, a classical olfactory test, olfactory dysfunction was 
not correlated with PD severity.5 A recent longitudinal study 
found no relationship between olfactory function and PD 
progression, including patient age, PD stage, and duration. 
Some PD patients have been found to recover from olfactory 
deficits on Sniffin Stick testing.10 Other studies have found 
a significant association between hyposmia and PD stage.6,7 
Olfactory function was shown to be impaired in patients with 
more than HY III than in those with HY I and II disease.6 
Odor discrimination was lost with motor disease progression 
according to UPDRS and HY classification.7 Serial olfactory 
examination using the Sniffin Stick test was performed in five 
de novo PD patients. Olfactory function worsened in three 
patients, and the degree of hyposmia was attenuated in one 
patient.8 The present study revealed statistically significant 
differences in olfactory function between HY II, III, and IV 
PD patients and controls. Three HY I patients (25%) also 
showed hyposmia. Predictive studies of hyposmia in PD 
have also been reported.11–14 Of 361 asymptomatic Dutch 
relatives of PD patients, 40 had hyposmia. After two years 
of follow-up, four hyposmic relatives (10%) developed PD.12 
In another Germany study of 30 patients with idiopathic 
hyposmia, PD developed in two patients (7%) during two 
years of follow-up.13
In addition to those patients with preclinical PD and signs 
of hyposmia, the present study supports the possibility that 
smell dysfunction could start in a subset of HY I patients. 
Previous neuropathologic research has mentioned that dop-
aminergic neurons in the olfactory bulb are potentiated in 
the early stages of PD by a compensatory mechanism against 
the loss of dopaminergic neurons in the basal ganglia.15 Such 
dopaminergic changes in the olfactory bulb may contribute 
to deteriorating olfactory function in PD patients. Thereafter, 
dopaminergic neuronal loss occurs in the olfactory bulb, so 
hyposmia may improve in patients with advanced PD. This 
hypothesis does not suggest a constant relationship between 
olfactory function and motor dysfunction in PD patients.
The UPSIT and Sniffin Stick tests use only one concen-
tration for each odorant. In these tests, a single odorant is 
judged by only one response as presence (“yes”) or absence 
(“no”). Odorants of wintergreen and pizza are distinguish-
able on UPSIT, and those odors show more sensitivity and 
specificity in PD patients.16 The Brief Smell Identification 
Test (BSIT), a simplified version of UPSIT, uses five kinds 
of odorants (gasoline, banana, pineapple, smoke, and cin-
namon). This smell test has shown that several odorants 
could be used to discriminate between PD patients and 
normal subjects.17 Previous reports of use of these studies 
have provided different sensitivities for different types of 
odorants in PD patients. The advantage of these tests is that 
they are easy and convenient to administer, but the olfac-
tory data include no quantitative evaluation using different 
concentrations of odorant.16,17
Odor D: γ–undecalactone
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Controls HY I HY II HY III HY IV
Figure 2D RT score of odorant D. There were no significant differences of odorant 
D scores between the five groups.
Odor E: skatol
6
4
2
0
Controls HY I HY II HY III HY IV
*† *†
*†
Figure 2E rT score of odorant e. compared with controls and hY I patients, rT 
scores for odorant E were higher significantly in HY II, III, and IV patients (F = 27.876 
and P , 0.001 by one-way AnOVA). 
Notes: *P , 0.01 by ryan’s method between the PD hY II, III and IV subgroups 
and controls; †P , 0.01 by ryan’s method between the hY I group and other hY 
groups.
Abbreviations:  AnOVA,  one-way  analysis  of  variance;  hY,  hoehn  and  Yale;   
PD, Parkinson’s disease; rT, recognition threshold. International Journal of General Medicine
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In comparison with the conventional smell tests used in 
Europe and the US, the TTO test was devised as a quantitative 
odor assessment method in Japan. Methodologic features of 
the TTO test include five odorants and seven or eight different 
concentrations of each odorant. A pilot TTO study showed that 
total RT score differed significantly between PD patients and 
age-matched controls, although PD stage and RT score were not 
analyzed for each odorant.18 In another small study of the TTO 
test in 10 PD patients and 10 controls, only two odorants were 
investigated, one pleasant and one unpleasant.19 In our study, 
we have analyzed olfactory function in a large number of PD 
patients (n = 89) by TTO examination using five odorants. Two 
kinds of odorants were found to be useful for olfactory evalua-
tion in these patients. Although no significant correlation existed 
between smell and motor dysfunction, some HY I patients had 
hyposmia. Besides the peripheral olfactory nerves and bulb, 
involvement of the corticobasal pathway or the olfactory limbic 
system could be a possible causative mechanism for hyposmia. A 
recent pathologic study mentioned no significant histochemical 
abnormalities of the olfactory epithelium between PD patients 
and control subjects.20 Therefore, the most crucial pathologic 
damage occurring in the peripheral and central olfactory systems 
remains unclear in PD patients with hyposmia.
The present study using the TTO test indicates that 
  hyposmia occurs in PD patients with HY II–IV disease. Total 
RT score and RT scores for methyl cyclopentenolone and skatol 
were useful for quantitative olfactory examination. These scores 
were not correlated with disease duration and HY stage in our 
patients. It is of interest that olfactory deficits were found in a 
minority of PD patients with HY I disease. Further longitudinal 
study is needed to clarify whether distinct clinical courses exist 
between HY I patients with and without hyposmia.
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